All In Biotech

Free tool

FAERS Monitor: Sogroya

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761156 or its brand name (Sogroya, Somapacitan-Beco). Reports on generic versions are filed under their own applications.

Reports

181

Serious

115

64% of reports

Hospitalization

51

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache15
  • pyrexia8
  • arthralgia7
  • fatigue7
  • vomiting7
  • hospitalisation6
  • pain in extremity6
  • rash6
  • abdominal pain5
  • asthenia5
  • condition aggravated5
  • decreased appetite5
  • dehydration5
  • hypoglycaemia5
  • seizure5

Reports by year received

View as table
YearReports
20222
20238
202458
202553
202660

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoglycaemiaSignal512.05.040
seizureSignal55.02.112
hospitalisationSignal64.52.113
dehydrationSignal54.41.810
headacheSignal152.81.716
pyrexiaSignal82.71.47
decreased appetite52.51.13
abdominal pain52.51.13
pain in extremity62.41.14
arthralgia72.00.92
condition aggravated51.90.81
vomiting71.70.82
rash61.60.71
asthenia51.50.71
fatigue71.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.